Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company.
The business
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Small Caps Research
No research on Clinuvel Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CUV based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Clinuvel Looking to Access Greater Market Share with Corporate Restructure and US Relocation
Clinuvel relocates HQ to US, trims up to 20% staff, refocuses on US pipeline; Nasdaq listing aims to boost US investor access and partnerships.
Clinuvel Showcases AI-Powered Vitiligo Assessment Tool at AAD Conference
Clinuvel unveils AI Vitiligo Visual Algorithm at AAD 2026, linking VVA to CUV107 Phase III; H1 FY26 revenue +4%, PAT -26% on higher costs.
Clinuvel Pharmaceuticals reaches patient recruitment milestone ahead of Phase III Scenesse vitiligo trial
Clinuvel Pharmaceuticals (ASX: CUV) has recruited more than 200 patients for a Phase III trial (CUV105) of its breakthrough Scenesse (afamelanotide 16mg) repigmentation therapy to treat vitiligo. The company is conducting the randomised 20-week trial at 37 sites across North America, Africa and Europe, with 57% of patients enrolled in the US. The last patient […]
Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide
Specialty pharmaceutical group Clinuvel Pharmaceuticals (ASX: CUV) has received promising outcomes from the final set of results from a study evaluating the DNA-repair capacity of its afamelanotide candidate. For the general population, and specifically for individuals with fair skin types who sunburn easily, the results indicate that afamelanotide can reduce oxidative damage and inflammatory reactions […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.